AUTHOR=Yan Nan , Wang Na , Zhang Peiling , Wang Gaoxiang , Mao Xia , Peng Dan , Kuang Dong , Chen Liting , Zhu Li , Zhou Jianfeng , Zhang Yicheng , Cao Yang 

TITLE=Case Report: Successful Chimeric Antigen Receptor T Cell Therapy in Haploidentical-Allogeneic Stem Cell Transplant Patients With Post-Transplant Lymphoproliferative Disorder

JOURNAL=Frontiers in Oncology

VOLUME=11

YEAR=2021

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.709370

DOI=10.3389/fonc.2021.709370

ISSN=2234-943X

ABSTRACT=<sec><title>Background</title><p>Epstein–Barr virus-associated post-transplant lymphoproliferative disorder (EBV-PTLD) is a potentially fatal complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Rituximab has been proven to dramatically improve the prognosis of patients with EBV reactivation and PTLD. However, reports on the curative management of refractory PTLD are scarce.</p></sec><sec><title>Case Presentation</title><p>In this report, we describe the successful management of two patients with EBV-PTLD with chimeric antigen receptor T-cell (CAR-T) therapy.</p></sec><sec><title>Conclusion</title><p>The present results demonstrated that patients with EBV-PTLD may benefit from CAR-T therapy and that the toxicity is manageable. Further studies are needed to verify these findings.</p></sec>